Janux Therapeutics, Inc.

NASDAQ:JANX

25.13 (USD) • At close June 4, 2025
Overview | Financials

Numbers are in millions (except for per share data and ratios) USD.

2025 Q12024 Q42024 Q32024 Q22024 Q12023 Q42023 Q32023 Q22023 Q12022 Q42022 Q32022 Q22022 Q12021 Q42021 Q32021 Q22021 Q12020 Q42020 Q32020 Q22020 Q1
Revenue 000.4398.8971.2522.4612.5171.0572.0482.8451.8132.3651.5891.6161.1590.4820.380000
Cost of Revenue 0000.5060.5320.5310.50.4710.45300.2490.1080.0810.0648.4064.7371.9250.9850.8340.6730.549
Gross Profit 000.4398.3910.721.932.0170.5861.5952.8451.5642.2571.5081.552-7.247-4.255-1.545-0.985-0.834-0.673-0.549
Gross Profit Ratio 0010.9430.5750.7840.8010.5540.77910.8630.9540.9490.96-6.253-8.828-4.0660000
Reseach & Development Expenses 25.05520.80618.61414.89814.0712.24111.89214.92415.86515.43413.73714.08610.18411.1698.4064.7371.9250.9850.8340.6730.549
General & Administrative Expenses 9.8428.21617.6677.8217.3436.3576.4386.8816.4645.6776.0985.544.9473.9373.6561.9970.7390.670.4220.4330.277
Selling & Marketing Expenses 000-0.506-0.5320000000000000000
SG&A 9.8428.21617.6677.3156.8116.3576.4386.8816.4645.6776.0985.544.9473.9373.6561.9970.7390.670.4220.4330.277
Other Expenses 000-14.8980-7.0674.24502.82200000.07400000-1.245-0.49
Operating Expenses 34.89729.02236.28122.21320.88118.59818.3321.80522.32921.11119.83519.62615.13115.10612.0626.7342.6641.6551.2561.1060.826
Operating Income -34.897-29.022-35.842-13.822-20.161-16.137-15.813-20.748-20.281-18.266-18.022-17.261-13.542-13.49-10.903-6.252-2.284-1.655-1.256-1.106-0.826
Operating Income Ratio 00-81.645-1.554-16.103-6.557-6.282-19.629-9.903-6.42-9.94-7.299-8.522-8.348-9.407-12.971-6.0110000
Total Other Income Expenses Net 11.3898.8067.7837.8635.4014.3794.2453.242.8222.2011.3260.3730.1320.0740.1370.046000-1.354-0.587
Income Before Tax -23.508-20.216-28.059-5.959-14.76-11.758-11.568-17.508-17.459-16.065-16.696-16.888-13.41-13.416-10.766-6.206-2.284-1.655-1.256-2.46-1.413
Income Before Tax Ratio 00-63.916-0.67-11.789-4.778-4.596-16.564-8.525-5.647-9.209-7.141-8.439-8.302-9.289-12.876-6.0110000
Income Tax Expense 00000.4890.953-0.50.349-0.4530-2.652-0.373-0.264-0.0740.1370.046000-1.136-0.393
Net Income -23.508-20.216-28.059-5.959-14.76-11.758-11.568-17.508-17.459-16.065-14.044-16.515-13.146-13.416-10.766-6.206-2.284-1.655-1.256-2.46-1.413
Net Income Ratio 00-63.916-0.67-11.789-4.778-4.596-16.564-8.525-5.647-7.746-6.983-8.273-8.302-9.289-12.876-6.0110000
EPS -0.38-0.36-0.51-0.11-0.3-0.25-0.25-0.42-0.42-0.39-0.34-0.4-0.32-0.33-0.26-0.62-0.057-0.13-0.1-0.2-0.11
EPS Diluted -0.38-0.36-0.51-0.11-0.3-0.25-0.25-0.42-0.42-0.39-0.34-0.4-0.32-0.33-0.26-0.62-0.057-0.13-0.1-0.2-0.11
EBITDA -34.897-28.51-35.332-13.316-19.629-15.606-15.313-20.277-19.828-17.863-17.773-17.153-13.461-13.352-10.876-6.239-2.275-1.646-1.255-2.35-1.314
EBITDA Ratio 00-80.483-1.497-15.678-6.341-6.084-19.184-9.682-6.279-9.803-7.253-8.471-8.262-9.384-12.944-5.9870000